After @ weeks , ezetimibe significantly reduced LDL-C by @ % after adjustment for placebo ( P < @ ) and produced significant reductions in total cholesterol ( @ % ) , nonhigh-density lipoprotein cholesterol ( @ % ) , and apolipoprotein B ( @ % ) ( P < @ for all ) .